Cariprazine for treating psychosis: an updated meta-analysis.

IF 2.9 4区医学 Q2 PSYCHIATRY

International Journal of Psychiatry in Clinical Practice Pub Date : 2023-03-01 DOI:10.1080/13651501.2022.2071740

Marcelo B Generoso, Ivan Taiar, Quirino Cordeiro, Pedro Shiozawa, Siegfried Kasper

{"title":"Cariprazine for treating psychosis: an updated meta-analysis.","authors":"Marcelo B Generoso, Ivan Taiar, Quirino Cordeiro, Pedro Shiozawa, Siegfried Kasper","doi":"10.1080/13651501.2022.2071740","DOIUrl":null,"url":null,"abstract":"Purpose: Early treatment of psychotic illness improves outcomes, reduces relapse rates and should not be delayed. Cariprazine is a promising antipsychotic drug and may be a valuable resource when clinicians are in doubt if psychotic symptoms are due to schizophrenia or bipolar disorder.Materials and methods: We conducted a systematic review and meta-analysis that included seven studies (n = 2896) analyzing the effect of cariprazine in psychotic symptoms assessed by the positive and negative symptoms scale (PANSS).Results: We found cariprazine to be significantly superior to placebo (Hedges' g = 0.40; 95% CI 0.32-0.49) for acute psychosis independently of primary psychiatric diagnosis and also to be superior to placebo for both schizophrenia (Hedges' g = 0.39; 95% CI 0.29-0.50) and bipolar patients (Hedges' g = 0.43; 95% CI 0.27-0.58).Conclusions: We propose that cariprazine may be useful in treating psychosis independently of nosological differentiation at the beginning of the treatment Key pointsEarly treatment of psychotic illness with antipsychotic medications improves outcomes and reduces relapse rates.Cariprazine was found to be significantly superior to placebo for acute psychosis independently of primary psychiatric diagnosis.Cariprazine may be useful in treating psychosis independently of nosological differentiation between schizophrenia and bipolar disorder at the beginning of the treatment.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":"27 1","pages":"107-109"},"PeriodicalIF":2.9000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Psychiatry in Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13651501.2022.2071740","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Early treatment of psychotic illness improves outcomes, reduces relapse rates and should not be delayed. Cariprazine is a promising antipsychotic drug and may be a valuable resource when clinicians are in doubt if psychotic symptoms are due to schizophrenia or bipolar disorder.

Materials and methods: We conducted a systematic review and meta-analysis that included seven studies (n = 2896) analyzing the effect of cariprazine in psychotic symptoms assessed by the positive and negative symptoms scale (PANSS).

Results: We found cariprazine to be significantly superior to placebo (Hedges' g = 0.40; 95% CI 0.32-0.49) for acute psychosis independently of primary psychiatric diagnosis and also to be superior to placebo for both schizophrenia (Hedges' g = 0.39; 95% CI 0.29-0.50) and bipolar patients (Hedges' g = 0.43; 95% CI 0.27-0.58).

Conclusions: We propose that cariprazine may be useful in treating psychosis independently of nosological differentiation at the beginning of the treatment Key pointsEarly treatment of psychotic illness with antipsychotic medications improves outcomes and reduces relapse rates.Cariprazine was found to be significantly superior to placebo for acute psychosis independently of primary psychiatric diagnosis.Cariprazine may be useful in treating psychosis independently of nosological differentiation between schizophrenia and bipolar disorder at the beginning of the treatment.

查看原文本刊更多论文

卡吡嗪治疗精神病:一项最新荟萃分析。

目的:早期治疗精神病可改善预后，降低复发率，不应延误治疗。卡吡嗪是一种很有前途的抗精神病药物，当临床医生怀疑精神病症状是否由精神分裂症或双相情感障碍引起时，它可能是一种有价值的资源。材料和方法:我们进行了一项系统回顾和荟萃分析，包括7项研究(n = 2896)，通过阳性和阴性症状量表(PANSS)评估卡吡嗪对精神病症状的影响。结果:我们发现卡吡嗪显著优于安慰剂(Hedges’g = 0.40;95% CI 0.32-0.49)在独立于原发性精神诊断的急性精神病方面也优于安慰剂在两种精神分裂症方面(Hedges’g = 0.39;95% CI 0.29-0.50)和双相情感障碍患者(Hedges’g = 0.43;95% ci 0.27-0.58)。结论:我们认为，卡吡嗪可能在治疗初期独立于疾病分异的精神病治疗中是有用的。关键词:早期使用抗精神病药物治疗精神病可改善预后，降低复发率。Cariprazine在治疗急性精神病方面的效果明显优于安慰剂，与最初的精神病诊断无关。在治疗开始时，卡吡嗪可能对独立于精神分裂症和双相情感障碍的疾病区分的精神病有帮助。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Psychiatry in Clinical Practice 医学-精神病学

CiteScore

6.00

自引率

3.30%

发文量

审稿时长

>12 weeks

期刊介绍： International Journal of Psychiatry in Clinical Practice provides an international forum for communication among health professionals with clinical, academic and research interests in psychiatry. The journal gives particular emphasis to papers that integrate the findings of academic research into realities of clinical practice. Focus on the practical aspects of managing and treating patients. Essential reading for the busy psychiatrist, trainee and interested physician. Includes original research papers, comprehensive review articles and short communications. Key words: Psychiatry, Neuropsychopharmacology, Mental health, Neuropsychiatry, Clinical Neurophysiology, Psychophysiology, Psychotherapy, Addiction, Schizophrenia, Depression, Bipolar Disorders and Anxiety.